Anthony Hagen
Advertisement
Articles by Anthony Hagen
The FDA will reassess 6 indications for immune checkpoint inhibitors that were granted accelerated approval but failed to prove clinical benefit in confirmatory trials.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Enlicitide, First Oral PCSK9 for High Cholesterol
2
SYNCHRONIZE-1 Through a Hepatologist's Lens: Liver Fat Reduction, Visceral Fat, and What Comes Next
3
Beyond GLP-1: The Biological Case for Dual Incretin Therapy in MASH
4
Stem Cell Transplant Outperforms DMTs in Drug-Resistant Relapsing MS
5